A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Clinical trial NCT05325866 · TERMINATED
Trial details
- NCT number
- NCT05325866
- Sponsor
- Amgen
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-23
- Primary completion
- 2026-01-28
- Enrollment
- 260
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.